26 patents
Utility
Peptides
16 Jan 24
The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
Filed: 4 Nov 22
Utility
Methods and Compositions
4 Jan 24
The present invention provides polypeptides capable of targeting antigens, such as neoantigens, to particular immune cells, and associated therapeutic methods.
PETER ELLMARK, PER NORLEN, KARIN HAGERBRAND
Filed: 30 Mar 21
Utility
Polypeptides
10 Oct 23
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 13 Apr 21
Utility
Novel Peptides
5 Oct 23
The present invention relates to novel bispecific polypeptides, such as antibodies, and their use in the treatment of cancers, particularly cancers expressing carcinoembryonic antigen (CEA).
Peter Ellmark, Karin Hagerbrand, Laura Varas, Mattias Levin, Anna Säll, Laura von Schantz
Filed: 4 Nov 22
Utility
Novel ANTI-CD137 Antibodies and Uses Thereof
21 Sep 23
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 10 Nov 22
Utility
Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods
15 Aug 23
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Van Citters, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 20 Jul 18
Utility
Anti-CD137 antibodies and uses thereof
27 Dec 22
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 21 Nov 17
Utility
Oncofetal antigen binding proteins and related compositions and methods
26 Apr 22
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 21 Feb 19
Utility
Novel Polypeptides
10 Mar 22
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen.
Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
Filed: 17 Dec 19
Utility
Novel Polypeptides
3 Mar 22
The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of targeting a dendritic cell, and a second binding domain, designated B2, which is capable of targeting a tumour cell-associated antigen.
Anna Sall, Peter Ellmark, Adnan Deronic, Fredrika Carlsson, Karin Hagerbrand, Laura Von Schantz
Filed: 17 Dec 19
Utility
Novel Polypeptides
24 Feb 22
The present invention provides bispecific antibodies of an antibody format, and which comprise one or more Fab fragments and an immunoglobulin molecule.
Anna Sall, Laura Von Schantz, Anneli Nilsson, Barnabas Nyesiga, Jessica Petersson, Mattias Levin
Filed: 17 Dec 19
Utility
Combination Therapies with Anti CD40 Antibodies
30 Dec 21
The present invention relates to combination therapies for treating a solid tumour in a subject.
Peter Ellmark, Per Norlen, Niina Veitonmaki
Filed: 15 Sep 21
Utility
Combination therapies with anti CD40 antibodies
19 Oct 21
The present invention relates to combination therapies for treating a solid tumour in a subject.
Peter Ellmark, Per Norlen, Niina Veitonmaki
Filed: 12 Aug 15
Utility
Novel Polypeptides
5 Aug 21
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 13 Apr 21
Utility
Polypeptides
18 May 21
The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Niina Veitonmaki, Laura Von Schantz
Filed: 20 May 16
Utility
Polypeptides
14 Sep 20
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 2 Feb 20
Utility
Antigen Binding Proteins Binding to 5T4 and 4-1BB and Related Compositions and Methods
15 Jul 20
The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB.
David Bienvenue, Gabriela Hernandez-Hoyos, Lynda Misher, Danielle Mitchell, Peter Ellmark, Anna Sall, Christina Furebring, Laura von Schantz, Sara Fritzell, Laura Varas
Filed: 19 Jul 18
Utility
Anti-CD137 antibodies and uses thereof
22 Jun 20
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with binding specificity for domain 2 of human CD137 which are capable of inhibiting the binding of a reference antibody to human CD137.
Peter Ellmark, Sara Fritzell, Christina Furebring, Jessica Petersson, Anna Sall, Karin Enell Smith, Laura Varas, Laura Von Schantz, Niina Veitonmaki
Filed: 16 Jul 19
Utility
Novel Polypeptides
17 Jun 20
The present invention provides a bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain capable of specifically binding to a first T cell target, and a second binding domain capable of specifically binding to a second T cell target, wherein the first and second T cell targets are different targets.
Peter Ellmark, Christina Furebring, Per Norlen, Eva Dahlen, Sara Fritzell, Laura Von Schantz, Niina Veitonmaki
Filed: 2 Feb 20
Utility
Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells
4 May 20
The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer.
Peter Bo Joakim Ellmark, Eva Maria Dahlen
Filed: 7 May 17